Ventripoint Announces Collaboration with Ascend Cardiovascular

(TheNewswire)

Toronto, Ontario – The Newswire –
August 10,  2023


– Ventripoint Diagnostics Ltd.
(”


Ventripoint


” or the ”


Company


“), (TSXV:VPT


)


;


(


OTC:VPTDF) is thrilled to announce that Ventripoint and
Ascend Cardiovascular, a leading provider of cardiovascular IT
solutions, have solidified a strategic collaboration. The two
companies have signed a letter of intent to explore joint research and
development initiatives, knowledge sharing, and combining  efforts to
bring innovative AI-based solutions to the market.

Ascend Cardiovascular has over two decades of
experience in cardiovascular IT and is an expert in cardiology
workflow. Ascend’s clinical reporting, device interfaces, and
analytics are used daily by some of the top institutions and hospital
systems in North America.

The teamwork  between Ventripoint and Ascend leverages
the strengths and expertise of both Ascend and Ventripoint to enhance
cardiovascular diagnostics and improve patient care. By combining the
capabilities of Ventripoint and Ascend, both companies aim to develop
and integrate solutions to improve diagnostic accuracy, streamline
workflows, and enhance patient experience. Ascend intends to resell
Ventripoint products developed through this partnership and integrated
with Ascend’s cardiovascular IT platform.

“This collaboration with Ascend Cardiovascular is
part of Ventripoint’s mission to elevate cardiac care by providing
better tools for clinicians.  We are excited about what the two
companies can accomplish by joining efforts,” stated Dr. Alvira
Macanovic, President & CEO of Ventripoint.

This coordination  will include exploring joint
research and development initiatives aimed at enhancing existing
cardiovascular diagnostic technologies and identifying new
opportunities.


This may include joint
projects, knowledge sharing, and collaborative efforts to seek
regulatory approvals and commercialize new products or services
including, where applicable, co-marketing and sales support
activities

“Ascend is on a mission to provide a fully
integrated, best-of-breed cardiovascular workflow solution to its
customers. Integration with Ventripoint’s innovative solution for 3D
visualization will provide tremendous value to pediatric and adult
echocardiographers in the care of their most complex patients,”
stated Dr. Jeff Soble, CEO of Ascend Cardiovascular.

Both Ventripoint and Ascend are excited about the
potential impact of this collaboration within the field of
cardiovascular diagnostics. Ascend brings their clinical and industry
knowledge, along with its proprietary structured reporting, and its
echocardiogram DICOM viewer to the collaboration.  Ventripoint brings
its proprietary AI-based diagnostic technologies, research
capabilities, and technical expertise in cardiovascular imaging and
analysis.  By combining the unique expertise and resources of both
companies, new solutions can be made that address existing challenges
within the industry.

About Ventripoint Diagnostics
Ltd.

Ventripoint


has become an
industry leader in the application of AI (Artificial Intelligence) to
echocardiography. Ventripoint’s VMS products are powered by its
proprietary KBR technology, which is the result of a decade of
development and provides accurate volumetric cardiac measurements
equivalent to MRI. This affordable, gold-standard alternative allows
cardiologists greater confidence in the management of their patients.
Providing better care to patients serves as a springboard and basic
standard for all of Ventripoint’s products that guide our future
developments. In addition, VMS+ is versatile and can be used with all
ultrasound systems from any vendor supported by regulatory market
approvals in the U.S., Europe and Canada.  Learn more:
 www.ventripoint.com.

About Ascend Cardiovascular

ASCEND Cardiovascular is a leader in innovating
cardiovascular solutions that empower the provider community to
improve cardiovascular care. Designed with openness in mind, our
solutions integrate with EHRs, medical devices, and other systems to
deliver seamless workflows that span procedure types and modalities. A
complete cardiovascular solution, ASCEND provides structured
reporting, image visualization, collaboration, and analytics that
improve efficiency, outcomes, and ROI. With decades of experience and
a practicing cardiologist at our helm, the ASCEND team brings
unparalleled “know how” in cardiology workflow, collaboration, and
IT offering limitless opportunities to improve clinical, operational,
and quality performance. Learn more:

www.ascendcv.com

.

For


further information, please
contact:

Jonathan Robinson CFA

[email protected]

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this news release.

Forward


Looking Statements

This news release contains forward-looking statements
and forward-looking information within the meaning of applicable
securities laws. The use of any of the words “expect”,
“anticipate”, “continue”, “estimate”,
“objective”, “ongoing”, “may”,
“will”, “project”, “should”,
“believe”, “plans”, “intends” and similar
expressions are intended to identify forward-looking information or
statements. The forward-looking statements and information are based
on certain key expectations and assumptions made by the Company.
Although the Company believes that the expectations and assumptions on
which such forward-looking statements and information are based are
reasonable, undue reliance should not be placed on the forward-looking
statements and information because the Company can give no assurance
that they will prove to be correct.

Since forward-looking statements and information
address future events and conditions, by their very nature they
involve inherent risks and uncertainties. Actual results could differ
materially from those currently anticipated due to a number of factors
and risks. Factors which could materially affect such forward-looking
information are described in the risk factors in the Company’s most
recent annual management’s discussion and analysis that is available
on the Company’s profile on SEDAR at

www.sedar.com.

Readers are
cautioned that the foregoing list of factors is not exhaustive. The
forward-looking statements included in this news release are expressly
qualified by this cautionary statement. The forward-looking statements
and information contained in this news release are made as of the date
hereof and the Company undertakes no obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws.

Copyright (c) 2023 TheNewswire – All rights reserved.